throbber
Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 1 of 13 PageID: 1
`
`
`
`John E. Flaherty
`Cynthia S. Betz
`McCARTER & ENGLISH, LLP
`Four Gateway Center
`100 Mulberry St.
`Newark, New Jersey 07102
`(973) 622-4444
`jflaherty@mccarter.com
`cbetz@mccarter.com
`
`OF COUNSEL:
`Mark N. Reiter (pro hac vice forthcoming)
`Philip Spear (pro hac vice forthcoming)
`GIBSON, DUNN & CRUTCHER LLP
`2001 Ross Avenue #2100
`Dallas, Texas 75201
`(214) 698-3369
`mreiter@gibsondunn.com
`pspear@gibsondunn.com
`
`David Glandorf (pro hac vice forthcoming)
`GIBSON, DUNN & CRUTCHER LLP
`1801 California Street, Suite 4200
`Denver, CO 80202-2642
`Tel.: (303) 298-5726
`dglandorf@gibsondunn.com
`Attorneys for Plaintiff
`Merck Sharp & Dohme LLC
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`MERCK SHARP & DOHME LLC,
`
`
`
`
`Plaintiff,
`
` Civil Action No. ___________________
`
`v.
`
`GLAND PHARMA LIMITED,
`
`
`
`
`
`
`
`
`
`Defendant.
`
`Electronically Filed
`
`
`
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 2 of 13 PageID: 2
`
`
`
`COMPLAINT FOR PATENT INFRINGEMENT
`
`Plaintiff Merck Sharp & Dohme LLC (“Merck” or “Plaintiff”), by and through its
`
`undersigned attorneys, hereby files this Complaint for Patent Infringement against Defendant
`
`Gland Pharma Limited (“Gland” or “Defendant”) and alleges as follows:
`
`NATURE OF THE ACTION
`
`1.
`
`This is an action for patent infringement of U.S. Patent Nos. 9,023,790 (the “’790
`
`Patent”) and 9,358,297 (the “’297 Patent”) arising under the patent laws of the United States,
`
`Title 35, United States Code, § 100 et seq., and, in particular, under 35 U.S.C. § 271(e). Gland
`
`notified Merck pursuant to 21 U.S.C. § 355(j)(2)(B)(ii) (the “Notice Letter”) that Gland is the
`
`owner of Abbreviated New Drug Application (“ANDA”) No. 217553, (the “Gland ANDA”),
`
`which Gland filed or caused to be filed under 21 U.S.C. § 355(j) with the United States Food and
`
`Drug Administration (“FDA”) for approval to engage in the commercial manufacture, use or sale
`
`of a generic version of Merck’s NOXAFIL® (posaconazole) intravenous (infusion) solution, 300
`
`mg/16.7 mL (18 mg/mL), which is sold in the United States. The Gland posaconazole
`
`intravenous solution product described in the Gland ANDA is referred to herein as the “Generic
`
`Posaconazole IV Solution Product.”
`
`THE PARTIES
`
`2.
`
`Plaintiff Merck is a corporation organized and existing under the laws of the State
`
`of New Jersey, having a principal place of business at 126 E Lincoln Ave Rahway, NJ, 07065-
`
`4607. Merck is a global, research-driven pharmaceutical company that discovers, develops,
`
`manufactures and markets a broad range of innovative products to improve health. Merck Sharp
`
`& Dohme LLC is the surviving entity after a merger with Merck Sharp & Dohme Corp., which
`
`was the previous owner of Merck’s NOXAFIL® product and the patents and NDA covering the
`
`
`
`
`
`1
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 3 of 13 PageID: 3
`
`
`
`same.
`
`3.
`
`On information and belief, Defendant Gland is a corporation organized and
`
`existing under the laws of India, with a place of business at Survey No. 143-148, 150 & 151
`
`Near Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal Gandimaisamma Mandal Medchal-
`
`Malkjgiri District, Hyderabad, Telangana, 500043 India. On information and belief Gland is in
`
`the business of, among other things, manufacturing, promoting, marketing, selling, offering for
`
`sale, using, distributing, and importing into the United States, generic versions of branded
`
`pharmaceutical drugs for the U.S. market.
`
`JURISDICTION AND VENUE
`
`4.
`
`5.
`
`This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331, 1338(a).
`
`This Court has personal jurisdiction over Gland by virtue of its presence in New
`
`Jersey, having conducted business in New Jersey, having availed itself of the rights and benefits
`
`of New Jersey law such that it should reasonably anticipate being haled into court in this judicial
`
`district, and having engaged in systematic and continuous contacts with the State of New Jersey
`
`through the marketing and sales of generic drug products within this judicial district, through the
`
`receipt of revenue from the sales and marketing of generic drug products within this judicial
`
`district, and through its pursuit of regulatory approval for its Generic Posaconazole IV Solution
`
`Product to market and sell its Generic Posaconazole IV Solution Product, if approved, in this
`
`judicial district and to residents of this judicial district, and having sent or caused to have sent the
`
`Notice Letter to Merck in New Jersey, prompting the filing of this lawsuit.
`
`6.
`
`According to Gland, it has filed 139 ANDAs in the United States and has had 100
`
`approved. See Gland Pharma Limited 2021-2022 Annual Report, pg. 35 available at
`
`https://glandpharma.com/images/Annual_Report_2021-22_(Double_Page).pdf. Gland’s website
`
`
`
`
`
`2
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 4 of 13 PageID: 4
`
`
`
`further states that Gland has “a global footprint across 60 countries, including the United States.”
`
`See Home, available at https://glandpharma.com/ (last visited September 8, 2022):
`
`
`7.
`
`Although this Court has personal jurisdiction over Gland for at least the reasons
`
`set forth above, in the absence of such personal jurisdiction in any single state, a foreign entity
`
`such as Gland is subject to jurisdiction throughout the United States. See Fed. R. Civ. P. 4(k)(2);
`
`Merial Ltd. v. Cipla Ltd., 681 F.3d 1283, 1293–94 (Fed. Cir. 2012).
`
`8.
`
`Upon information and belief, Gland has previously submitted to the jurisdiction of
`
`this Court and has further previously availed itself of this Court by asserting counterclaims in at
`
`least the following actions: Fresenius Kabi Deutschland GmbH et al v. Gland Pharma Limited,
`
`No. 3:20-cv-12347 (D.N.J.) (Sept. 4, 2020); Merck Sharp & Dohme B.V. et al v. Gland Pharma
`
`Limited, No. 2:20-cv-02750 (D.N.J.) (Mar. 12, 2020); Chiesi USA Inc. et al v. Gland Pharma
`
`Limited, No. 2:19-cv-18565 (D.N.J.) (Sept. 30, 2019); Medicure Int’l, Inc. v. Gland Pharma
`
`Limited, No. 2:18-cv-16246 (D.N.J.) (Nov. 16, 2018).
`
`9.
`
`Venue is proper as to Gland in this judicial district under 28 U.S.C. § 1391(c)(3)
`
`because Gland is a foreign entity who may be sued in any judicial district. See In re HTC Corp.,
`
`889 F.3d 1349, 1357 (Fed. Cir. 2018).
`
`
`
`
`
`3
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 5 of 13 PageID: 5
`
`
`
`NOXAFIL®
`
`10. Merck is the holder of New Drug Application (“NDA”) N205596 for the
`
`manufacture and sale of posaconazole intravenous solution, which Merck markets and sells
`
`under the registered trademark NOXAFIL® (“NOXAFIL® for Injection”). NOXAFIL® for
`
`Injection is approved for the prophylaxis of invasive fungal infections in high risk patients.
`
`11.
`
`NOXAFIL® for Injection is an embodiment of one or more claims of the ’790
`
`Patent and the ’297 Patent (collectively, the “Patents-in-Suit”). The Patents-in-Suit are listed in
`
`the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange
`
`Book”) for NOXAFIL®.
`
`PATENTS-IN-SUIT
`
`12.
`
`The ’790 Patent, entitled “Posaconazole Intravenous Solution Formulations
`
`Stabilized by Substituted β-Cyclodextrin,” was duly and legally issued by the USPTO on May 5,
`
`2015. The Orange Book lists the expiration date of the ’790 Patent as July 4, 2031. Merck is the
`
`owner of all title, right and interest in and to the ’790 Patent by assignment. A copy of the ’790
`
`Patent is attached as Exhibit A.
`
`13.
`
`The ’297 Patent, entitled “Posaconazole Intravenous Solution Formulations
`
`Stabilized by Substituted β-Cyclodextrin” was duly and legally issued by the USPTO on June 7,
`
`2016. The Orange Book lists the expiration date of the ’297 Patent as June 24, 2031. Merck is
`
`the owner of all title, right and interest in and to the ’297 Patent by assignment. A copy of the
`
`’297 Patent is attached as Exhibit B.
`
`GLAND’S ANDA
`
`14.
`
`Gland filed or caused to be filed the Gland ANDA with the FDA, seeking FDA
`
`approval to market and sell within the United States the Generic Posaconazole IV Solution
`
`Product before the expiration of the Patents-in-Suit.
`
`
`
`
`
`4
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 6 of 13 PageID: 6
`
`
`
`15.
`
`On information and belief, the Gland ANDA identified Merck’s NOXAFIL® for
`
`Injection product and included a written certification, as required by 21 U.S.C.
`
`§ 355(j)(2)(A)(vii)(IV), alleging that the claims of the Patents-in-Suit are invalid or otherwise
`
`will not be infringed by the Generic Posaconazole IV Solution Product.
`
`16.
`
`On or about August 1, 2022, Merck received the Notice Letter from Gland, dated
`
`July 29, 2022, stating that pursuant to § 505(j)(2)(B)(ii) of the Federal Food Drug and Cosmetic
`
`Act, 21 U.S.C. § 355(j)(2)(B)(ii), Gland had submitted the Gland ANDA to the FDA.
`
`17.
`
`In its letter to Merck, Gland stated its allegation that the claims of the Patents-in-
`
`Suit are invalid.
`
`18.
`
`Gland does not contest that at least the pharmaceutical composition claims of the
`
`’790 and ’297 Patents would be infringed by the manufacture, use, or sale of the Generic
`
`Posaconazole IV Solution Product, unless those claims are found to be invalid.
`
`19.
`
`By filing or causing to be filed the Gland ANDA, Gland necessarily represented
`
`to the FDA that the Generic Posaconazole IV Solution Product has the same active ingredient as
`
`NOXAFIL® for Injection, has the same method of administration, dosage form, and strength as
`
`NOXAFIL® for Injection and is bioequivalent to NOXAFIL® for Injection.
`
`COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 9,023,790
`
`20. Merck incorporates by reference Paragraphs 1–19 of this Complaint as if fully set
`
`forth herein.
`
`21.
`
`By filing or causing to be filed the Gland ANDA with the FDA under 21 U.S.C. §
`
`355(j) to obtain approval to engage in the commercial manufacture, use or sale of the Generic
`
`Posaconazole IV Solution Product before the expiration of the ’790 Patent, Gland committed an
`
`act of infringement under 35 U.S.C. § 271(e)(2).
`
`
`
`
`
`5
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 7 of 13 PageID: 7
`
`
`
`22.
`
`If Gland commercially makes, uses, offers to sell or sells the Generic
`
`Posaconazole IV Solution Product within the United States, or imports the Generic Posaconazole
`
`IV Solution Product into the United States, or induces or contributes to any such conduct during
`
`the term of the ’790 Patent, Gland would further infringe at least one claim of the ’790 Patent
`
`under 35 U.S.C. §§ 271(a), (b), and/or (c).
`
`23.
`
`Gland’s commercial manufacture, use, offer to sell, or sale of the Generic
`
`Posaconazole IV Solution Product within the United States, or importation of the Generic
`
`Posaconazole IV Solution Product into the United States, during the term of the ’790 Patent,
`
`would infringe at least one claim of the ’790 Patent.
`
`24.
`
`Upon approval of the Gland ANDA, and the commercial marketing of the
`
`Generic Posaconazole IV Solution Product, Gland would actively induce and/or contribute to
`
`infringement of at least one claim of the ’790 Patent. At least in light of the prescribing
`
`instructions Gland proposes to provide in connection with the Generic Posaconazole IV Solution
`
`Product, Gland will induce health care professionals, resellers, pharmacies, and end users of the
`
`Generic Posaconazole IV Solution Product to directly infringe one or more claims of the ’790
`
`Patent. Gland will encourage acts of direct infringement with knowledge of the ’790 Patent and
`
`knowledge that it is encouraging infringement.
`
`25.
`
`Gland had actual and constructive knowledge of the ’790 Patent prior to filing the
`
`Gland ANDA and was aware that the filing of the Gland ANDA with the request for FDA
`
`approval before the expiration of the ’790 Patent would constitute an act of infringement of the
`
`’790 Patent.
`
`
`
`
`
`6
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 8 of 13 PageID: 8
`
`
`
`26. Merck will be substantially and irreparably harmed by the infringing activities
`
`described above unless those activities are enjoined by this Court. Merck has no adequate
`
`remedy at law.
`
`COUNT II FOR INFRINGEMENT OF U.S. PATENT NO. 9,358,297
`
`27. Merck incorporates by reference Paragraphs 1–26 of this Complaint as if fully set
`
`forth herein.
`
`28.
`
`By filing or causing to be filed the Gland ANDA with the FDA under 21 U.S.C. §
`
`355(j) to obtain approval to engage in the commercial manufacture, use or sale of the Generic
`
`Posaconazole IV Solution Product before the expiration of the ’297 Patent, Gland committed an
`
`act of infringement under 35 U.S.C. § 271(e)(2).
`
`29.
`
`If Gland commercially makes, uses, offers to sell or sells the Generic
`
`Posaconazole IV Solution Product within the United States, or imports the Generic Posaconazole
`
`IV Solution Product into the United States, or induces or contributes to any such conduct during
`
`the term of the ’297 Patent, Gland would further infringe at least one claim of the ’297 Patent
`
`under 35 U.S.C. §§ 271(a), (b), and/or (c).
`
`30.
`
`Gland’s commercial manufacture, use, offer to sell, or sale of the Generic
`
`Posaconazole IV Solution Product within the United States, or importation of the Generic
`
`Posaconazole IV Solution Product into the United States, during the term of the ’297 Patent,
`
`would infringe at least one claim of the ’297 Patent.
`
`31.
`
`Upon approval of the Gland ANDA, and the commercial marketing of the
`
`Generic Posaconazole IV Solution Product, Gland would actively induce and/or contribute to
`
`infringement of at least one claim of the ’297 Patent. At least in light of the prescribing
`
`instructions Gland proposes to provide in connection with the Generic Posaconazole IV Solution
`
`
`
`
`
`7
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 9 of 13 PageID: 9
`
`
`
`Product, Gland will induce health care professionals, resellers, pharmacies, and end users of the
`
`Generic Posaconazole IV Solution Product to directly infringe one or more claims of the ’297
`
`Patent. Gland will encourage acts of direct infringement with knowledge of the ’297 Patent and
`
`knowledge that it is encouraging infringement.
`
`32.
`
`Gland had actual and constructive knowledge of the ’297 Patent prior to filing the
`
`Gland ANDA and was aware that the filing of the Gland ANDA with the request for FDA
`
`approval before the expiration of the ’297 Patent would constitute an act of infringement of the
`
`’297 Patent.
`
`33. Merck will be substantially and irreparably harmed by the infringing activities
`
`described above unless those activities are enjoined by this Court. Merck has no adequate
`
`remedy at law.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiff prays for judgment in its favor and against Defendant and
`
`respectfully requests the following relief:
`
`A.
`
`A judgment that Defendant has infringed one or more claims of the ’790
`
`Patent under 35 U.S.C. § 271(e)(2) by submitting the Gland ANDA;
`
`B.
`
`A judgment that Defendant has infringed one or more claims of the ’297
`
`Patent under 35 U.S.C. § 271(e)(2) by submitting the Gland ANDA;
`
`C.
`
`A judgment, pursuant to 35 U.S.C. § 271(e)(4)(B), preliminarily and
`
`permanently enjoining Defendant, its officers, agents, servants, employees, parents, subsidiaries,
`
`divisions, affiliates, from making, using, selling, offering to sell, or importing any product that
`
`infringes the ’790 Patent, including the product described in the Gland ANDA, prior to the
`
`expiration of the ’790 Patent, including any extensions;
`
`
`
`
`
`8
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 10 of 13 PageID: 10
`
`
`
`D.
`
`A judgment, pursuant to 35 U.S.C. § 271(e)(4)(B), preliminarily and
`
`permanently enjoining Defendant, its officers, agents, servants, employees, parents, subsidiaries,
`
`divisions, affiliates, from making, using, selling, offering to sell, or importing any product that
`
`infringes the ’297 Patent, including the product described in the Gland ANDA, prior to the
`
`expiration of the ’297 Patent, including any extensions;
`
`E.
`
`A judgment declaring that making, using, selling, offering to sell, or
`
`importing the product described in the Gland ANDA, or inducing or contributing to such
`
`conduct, would constitute infringement of the ’790 Patent by Defendant pursuant to 35 U.S.C.
`
`§ 271;
`
`F.
`
`A judgment declaring that making, using, selling, offering to sell, or
`
`importing the product described in the Gland ANDA, or inducing or contributing to such
`
`conduct, would constitute infringement of the ’297 Patent by Defendant pursuant to 35 U.S.C.
`
`§ 271;
`
`G.
`
`A judgment ordering that, pursuant to 35 U.S.C. § 271(e)(4)(A), the
`
`effective date of any approval of the Gland ANDA be a date that is not earlier than the expiration
`
`of the ’790 Patent or any later expiration of exclusivity to which Plaintiff is or becomes entitled;
`
`H.
`
`A judgment ordering that, pursuant to 35 U.S.C. § 271(e)(4)(A), the
`
`effective date of any approval of the Gland ANDA be a date that is not earlier than the expiration
`
`of the ’297 Patent or any later expiration of exclusivity to which Plaintiff is or becomes entitled;
`
`I.
`
`If Defendant, its officers, agents, servants, employees, parents,
`
`subsidiaries, divisions, affiliates, and those persons in active concert or participation with any of
`
`them commercially manufactures, uses, offers to sell, sells or imports the product described in
`
`the Gland ANDA prior to the expiration of the ’790 Patent or any later expiration of exclusivity
`
`
`
`
`
`9
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 11 of 13 PageID: 11
`
`
`
`to which Plaintiff is or becomes entitled, a judgment awarding Plaintiff monetary relief, together
`
`with interest;
`
`J.
`
`If Defendant, its officers, agents, servants, employees, parents,
`
`subsidiaries, divisions, affiliates, or those persons in active concert or participation with any of
`
`them commercially manufactures, uses, offers to sell, sells or imports the product described in
`
`the Gland ANDA prior to the expiration of the ’297 Patent or any later expiration of exclusivity
`
`to which Plaintiff is or becomes entitled, a judgment awarding Plaintiff monetary relief, together
`
`with interest;
`
`K.
`
`A declaration that this case is exceptional within the meaning of 35 U.S.C.
`
`§ 285 and awarding reasonable attorneys’ fees, costs and disbursement incurred as a result of this
`
`action; and
`
`L.
`
`Such other and further relief as the Court deems just and proper.
`
`
`
`
`
`
`
`* * *
`
`10
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 12 of 13 PageID: 12
`
`
`
`Dated: September 8, 2022.
`
`
`
`
`OF COUNSEL:
`
`Mark N. Reiter (pro hac vice forthcoming)
`Philip Spear (pro hac vice forthcoming)
`GIBSON, DUNN & CRUTCHER LLP
`2001 Ross Avenue #2100
`Dallas, TX 75201-6912
`(214) 698-3100
`mreiter@gibsondunn.com
`pspear@gibsondunn.com
`
`David Glandorf (pro hac vice forthcoming)
`GIBSON, DUNN & CRUTCHER LLP
`1801 California Street
`Denver, CO 80202-2642
`(303) 298-5726
`dglandorf@gibsondunn.com
`
`
`
`
`
`
`
`
`COUNSEL OF RECORD:
`
` /s/ John E. Flaherty
`John E. Flaherty
`Cynthia S. Betz
`McCARTER & ENGLISH, LLP
`Four Gateway Center
`100 Mulberry St.
`Newark, New Jersey 07102
`(973) 622-4444
`jflaherty@mccarter.com
`cbetz@mccarter.com
`
`
`Attorneys for Plaintiff
`Merck Sharp & Dohme LLC
`
`
`
`
`
`
`
`
`
`

`

`Case 2:22-cv-05461-JXN Document 1 Filed 09/08/22 Page 13 of 13 PageID: 13
`
`
`
`
`
`CERTIFICATION PURSUANT TO L. CIV. R. 11.2
`
`Pursuant to Local Civil Rule 11.2, I hereby certify that the matter in controversy is not the
`
`subject of any other action pending in any court, or of any pending arbitration or administrative
`
`proceeding.
`
`
`
`
`
`By: /s/ John E. Flaherty
`John E. Flaherty
`
`
`
`
`
`
`
`
`
`CERTIFICATION PURSUANT TO L. CIV. R. 201.1(d)
`
`Pursuant to Local Civil Rule 201.1, I hereby certify the above-captioned matter is not
`
`subject to compulsory arbitration in that, inter alia, the Plaintiff seeks non-monetary injunctive
`
`relief and the amount in controversy exceeds the $150,000 threshold of interest and costs and any
`
`claim for punitive damages.
`
`
`
`
`
`
`
`
`
` By: /s/ John E. Flaherty
`John E. Flaherty
`
`
`
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket